AlloVir, Inc.
AlloVir, Inc. (ALVR) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ALVR · as of Jun 9, 2026
Key Statistics
Explore AlloVir, Inc. Data
alvr stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 50.0%
Competitors & Peers
alvr competitorsALVR
ACHL
BLUE
GRNA
KRON
MGTAStock Performance
Full HistoryAbout AlloVir, Inc.
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to …
what is allovir, inc. · alvr stock overview · allovir, inc. company profile · who is allovir, inc. ceo · alvr NASDAQ · allovir, inc. headquarters · allovir, inc. business segments
About Stock Overview & Key Data
AlloVir, Inc. (ALVR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 30, 2020. As of the latest trading session, ALVR stock price is $9.81, with a market capitalization of $49.5M. The stock has returned -43.65% over the past 12 months and -5.22% year-to-date.
According to 8 Wall Street analysts, the consensus rating for AlloVir, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, AlloVir, Inc. reported revenue of — and net income of -$43.4M. For detailed data — including AlloVir, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, AlloVir, Inc. (ALVR) stock price is $9.81. The stock is traded on NASDAQ under the ticker symbol ALVR. The 52-week range is $7.96 – $24.15.